Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius AGSARTF 85 3-Year Book Growth Rate is 10.50% as of Jun. 2026, which is 33% below its 10-year median of 15.60. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $231.88 (Fairly Valued). The stock has 6 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Sartorius AG ranks better than 75.92% on this metric.
During the past 12 months, Sartorius AG's average Book Value per Share Growth Rate was 6.20% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 10.50% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 22.70% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 20.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Sartorius AG was 34.90% per year. The lowest was -1.60% per year. And the median was 15.60% per year.
Sartorius AG (OTCPK:SARTF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Sartorius AG 3-Year Book Growth Rate Related Terms
SARTF vs ISRG, BDX, MDLN: 3-Year Book Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG 3-Year Book Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Sartorius AG's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 10.50% mean?
Sartorius AG (SARTF) has a 3-Year Book Growth Rate of 10.50% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Sartorius AG and its competitors. This is 33% below median its historical median of 15.60. According to the industry distribution chart, Sartorius AG ranks #183 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 24.1%.
Is Sartorius AG's 3-Year Book Growth Rate too high?
Sartorius AG's current 3-Year Book Growth Rate of 10.50% is 33% below median its 10-year median of 15.60. The Medical Devices & Instruments industry median 3-Year Book Growth Rate is 2.35. Sartorius AG's value of 10.50% is 346.8% above this industry median. Based on the distribution chart, Sartorius AG ranks #183 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's 3-Year Book Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #183 out of 760 companies for 3-Year Book Growth Rate. This places Sartorius AG in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 2.35. Sartorius AG's value of 10.50% is 346.8% above this benchmark. While the company's 10-year median is 15.60 vs. the industry median of 2.35, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Book Growth Rate among Medical Devices & Instruments companies is 2.35, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current 3-Year Book Growth Rate of 10.50% is 346.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Sartorius AG and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Book Growth Rate is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current 3-Year Book Growth Rate is 10.50%, which is 33% below median its own 10-year median of 15.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Fairly Valued. The stock's GF Value™ is $231.88, compared to a current price of $212.80 — trading 8.2% below its estimated fair value. The current 3-Year Book Growth Rate is 10.50%, which is 33% below median its 10-year median of 15.60 and 346.8% above the Medical Devices & Instruments industry median of 2.35. Sartorius AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Sartorius AG (SARTF), the current 3-Year Book Growth Rate is 10.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 8.2% below its estimated GF Value™ of $231.88.
GuruFocus considers Sartorius AG to be Fairly Valued.
Key valuation signals for SARTF:
3-Year Book Growth Rate: 10.50% (33% below median its 10-year median of 15.60)
GF Value™: $231.88 vs. price of $212.80 (8.2% below fair value)
Industry Position: 346.8% above the Medical Devices & Instruments median (#183 of 760)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score
Get the complete analysis for SARTF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
